Previous close | 4.9000 |
Open | N/A |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 31.00 |
Expiry date | 2024-09-20 |
Day's range | 4.9000 - 8.4800 |
Contract range | N/A |
Volume | |
Open interest | N/A |
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA.
Director Jerome Zeldis of PTC Therapeutics Inc (NASDAQ:PTCT) executed a sale of 20,000 shares of the company on May 22, 2024, according to a recent SEC Filing.
Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.